STADA Arzneimittel AG (ETR:SAZ) received a €66.00 ($75.86) price target from equities research analysts at Kepler Capital Markets in a research note issued on Tuesday, July 11th. The firm currently has a “neutral” rating on the stock.
Other research analysts also recently issued reports about the company. Warburg Research set a €66.00 ($75.86) price target on STADA Arzneimittel AG and gave the company a “sell” rating in a report on Thursday, June 8th. S&P Global set a €66.00 ($75.86) target price on STADA Arzneimittel AG and gave the stock a “neutral” rating in a research note on Saturday, May 20th. Independent Research GmbH set a €66.00 ($75.86) target price on STADA Arzneimittel AG and gave the stock a “neutral” rating in a research note on Saturday, May 20th. Finally, Commerzbank Ag set a €66.00 ($75.86) target price on STADA Arzneimittel AG and gave the stock a “neutral” rating in a research note on Monday, July 3rd. Five research analysts have rated the stock with a hold rating, STADA Arzneimittel AG presently has an average rating of “Hold” and an average price target of €64.90 ($74.60).
STADA Arzneimittel AG (SAZ) opened at 65.454 on Tuesday. STADA Arzneimittel AG has a 12-month low of €41.40 and a 12-month high of €67.60. The stock’s 50 day moving average price is €63.85 and its 200 day moving average price is €58.96. The company has a market capitalization of €4.07 billion and a price-to-earnings ratio of 38.639.
TRADEMARK VIOLATION NOTICE: This story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://sportsperspectives.com/2017/07/23/stada-arzneimittel-ag-etrsaz-pt-set-at-66-00-by-kepler-capital-markets-2-updated.html.
STADA Arzneimittel AG Company Profile
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products.
Receive News & Ratings for STADA Arzneimittel AG Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for STADA Arzneimittel AG and related companies with MarketBeat.com’s FREE daily email newsletter.